Ibrahim Halil Sahin

Featured in: Favicon

nature.com Favicon

medscape.com Favicon

healio.com Favicon

amegroups.com Favicon

futuremedicine.com Favicon

cancernetwork.com Favicon

onlinelibrary.wiley.com Favicon

cco.amegroups.com

Articles

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

May 15, 2024 | cancernetwork.com | Seth I. Felder |Jessica Frakes |Manju George |Allison B. Rosen |Ibrahim Halil Sahin |Ibrahim Şahin

May 15, 2024OncologyONCOLOGY Vol 38, Issue 5Pages: 187-190Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)

Sep 7, 2023 | mdpi.com | Akshit Chitkara |Muhammad Arsalan Bakhtiar |Ibrahim Halil Sahin |Ibrahim Şahin |Dennis J. Hsu

3. Results 3.1. Study CharacteristicsTwo of the six trials selected evaluated trastuzumab deruxtecan, and one evaluated trastuzumab plus lapatinib. One trial evaluated pertuzumab plus trastuzumab emtansine, while one evaluated trastuzumab plus tucatinib, and one evaluated trastuzumab plus pyrotinib (Table 2). Regarding prior lines of treatment, the median number of prior lines was two and three in two trials and four and five in one trial each.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →